Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962102 · ClinicalTrials.gov registry record · Phase 2
Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
A Phase 2 study of Acute Kidney Injury and Critically Ill, sponsored by David Leaf.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02962102 is a Phase 2 study of Acute Kidney Injury and Critically Ill that has completed, run by David Leaf. The registered enrollment target is 150 participants, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02962102, a Phase 2 study of Acute Kidney Injury and Critically Ill, has completed, sponsored by David Leaf.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Calcitriol
- DRUG Calcifediol
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2020-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02962102
The ClinicalTrials.gov registry entry for NCT02962102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The listed sponsor is David Leaf, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 3 interventions - of which Placebos is the first listed.
NCT02962102 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02962102 about?
NCT02962102 is a clinical study titled "Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury". The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.
What is the current status of trial NCT02962102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-04-03. Estimated completion is 2020-08-06.
What conditions does trial NCT02962102 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Critically Ill.
What interventions are being tested in trial NCT02962102?
The interventions under investigation include: Placebos (DRUG), Calcitriol (DRUG), Calcifediol (DRUG).
Who is sponsoring clinical trial NCT02962102?
This trial is sponsored by David Leaf, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02962102 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.